

# Oncologists are Unaware of Safety Risks Due To Deficient Drug Labelling

Caroline M. Apovian,<sup>1,2</sup> Fatima Cody Stanford,<sup>1,3</sup> Christina R. Chow,<sup>4</sup> Brandon Fremd,<sup>4</sup> Theodore K. Kyle<sup>5</sup>

<sup>1</sup>Harvard Medical School, Boston, MA; <sup>2</sup>Brigham and Women's Hospital, Cambridge, MA; <sup>3</sup>Massachusetts General Hospital, Cambridge, MA; <sup>4</sup>Emerald Lake Safety, LLC, Newport Beach, CA; <sup>5</sup>ConsienHealth, Pittsburgh, PA

## Introduction

- Obesity has multiple comorbid conditions, including various cancers.
- FDA does not currently require drugs seeking approval to be tested in people with obesity (PwO), and drug manufacturers often exclude PwO from clinical trials to reduce heterogeneity.
- PwO are frequently prescribed medications that may be unsafe or ineffective for them.
- The half-life of posaconazole, a potent CYP3A4 inhibitor, is **almost doubled in PwO**, causing prolonged drug-drug interactions (DDIs) with oncology drugs that are CYP3A4 substrates.
- **The lack of prescribing language describing this phenomenon puts PwO at risk of adverse events.**

## Methods

An online survey of 100 board-certified US hematologists and oncologists who prescribe both posaconazole and oncology medications with half-life-based washouts was conducted to assess their knowledge of posaconazole's increased half-life in PwO and the impact of these findings on clinical practice.


## Key Takeaways

- Nearly all (96%) hematologists and oncologists knew the DDI risks when prescribing posaconazole and oncology medications.
- **Less than half (46%) were aware of posaconazole's increased half-life in PwO.**
- The majority (87%) expect to see this half-life information on posaconazole's drug label.
- **100% of oncologists will use this knowledge going forward.**

Without the necessary label information, most practitioners are – and will continue to be – **unaware of the prolonged safety risks** when treating PwO with posaconazole and oncology drugs.



Survey of 100 Oncologists Prescribing Posaconazole Together with Half-Life Delay Drugs



HARVARD MEDICAL SCHOOL



EMERALD LAKE SAFETY